New pill targets Hard-to-Treat cancers with RAS mutations

NCT ID NCT07189949

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests an experimental drug called HRS-2329 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 120 participants will take the drug by mouth, and researchers will monitor side effects and early signs of tumor control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-2329 tablet
What this could lead to: If successful, this could lead to a new targeted therapy option for people with advanced solid tumors that have specific RAS mutations or amplifications.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not shrink tumors or could cause side effects. Results may not apply to all RAS-mutant cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS HARBORING RAS MUTATIONS OR AMPLIFICATIONS

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300181, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.